menu

About

ReguGene Co., Ltd. is a pharmaceutical venture company founded on 3rd Sep 2018 by Professor Hiroshi Sugiyama at Graduate School of Science of Kyoto University and Professor Yasuhiko Kamikubo at Graduate School of Medicine of Kyoto University. Our aim is to supply medicines for intractable and rare diseases by developing DNA-targeting drugs utilizing cell permeable pyrrole-imidazole polyamides.

Detail

Technology

Pyrrole-Imidazole Polyamides

Pyrrole-Imidazole Polyamides (PI-Polyamides) are synthetic molecules developed by mimicking the structures of natural antibiotics, netropsin and distamycin. They have simple structures consisting of N-methylpyrrole, N-methylimidazole, and -alanine connected by amide bonds. Hairpin-shaped PI-Polyamides are often used to design to bind to a specific target DNA sequence. Professor Hiroshi Sugiyama has researched PI-Polyamides for more than 20 years and possesses methods and know-hows for the synthesis and evaluation of the activities.

PI-Polyamides as ON/OFF Switch of genes

PI-Polyamides which bind to a recognition sequence of a transcription factor can inhibit the binding of the transcription factor to DNA in live cells and suppress the transcription of the gene activated by the transcription factor (OFF switch). Conjugation of a DNA alkylating reagent with PI-Polyamides enables to suppress transcription even if their target sequences are not a binding site of a transcription factor.
Professor Hiroshi Sugiyama has also succeeded to enhance expression levels of gene clusters by using PI-Polyamides conjugates with HDAC inhibitor, HAT activator, and bromodomain inhibitor of HAT (ON switch).

Detail

Contact

Please contact using the form below.

NEWS

  • 2018-09-03
    ReguGene Co., Ltd. was established.
  • 2017-10-02
    2017/10/2–2018/3/31 Kyoto-Based Entrepreneurship Education Programs (Kyoto City) “Development of New Drugs to Control Gene Expression Related to Cancer etc. to Start-up a Company”
  • 2017-10-01
    2017/10/1–2018/3/31 Acceleration Transformative Research for Medical Innovation (ACT-MS) (Japan Agency for Medical Research and Development) “Creation of innovative anticancer drugs for Refractory Lung Cancer”
  • 2017-08-01
    2017/8/1–2020/3/31 Incubation Program (Kyoto University) “Drug Development Project Based on Pyrrole-Imidazole Polyamide Conjugates with Specific DNA Binding Capability”
過去のニュース一覧News Archive